The following is a summary of “Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma, ...

Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ...

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Study finds low peripheral blood lymphocyte count at diagnosis predicts worse overall survival in multiple myeloma patients.

Cancer researchers determine these survival rates with a measure called five ... but the most common type is called multiple myeloma, which begins in the bone marrow and can then spread throughout ...

New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

Thalidomide was the first immunomodulatory agent approved for use in myeloma. Although highly ... Overall response rate; OS: Overall survival; PFS: Progression-free survival; PR: Partial response ...

A new editorial was published in Oncoscience’s Volume 12 on January 14, 2025, titled “Pomalidomide improved immune profiles ...

Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.

The panelist discusses how real-world evidence for CAR T in relapsed/refractory multiple myeloma shows promising efficacy but ...

Sanofi’s Sarclisa (isatuximab) has been approved by the European Commission (EC) to treat adults with newly diagnosed ...